Nasdaq

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI ...

About TSLP and TSLPR BlockadeThymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where ...
Seeking Alpha

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Nasdaq

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...
Business Insider

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...
Hosted on MSN

Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug

Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 8, Upstream Bio announced that the first patient had been dosed in a Phase 2 ...